Correlation between Systemic Lupus Erythematosus Activity and Plasma Levels of Monomeric Prolactin and Macroprolactin

被引:7
作者
Ribeiro, Camila Toffoli [1 ]
Louzada Junior, Paulo [2 ]
Silva de Sa, Marcos Felipe [3 ]
机构
[1] Univ Fed Uberlandia, Fac Med Sci, Dept Gynecol & Obstet, Para Ave 1720, BR-38400902 Uberlandia, MG, Brazil
[2] Univ Sao Paulo, Fac Med Sci, Dept Internal Med, BR-14049 Ribeirao Preto, Brazil
[3] Univ Sao Paulo, Fac Med Sci, Dept Gynecol & Obstet, BR-14049 Ribeirao Preto, Brazil
关键词
Macroprolactin; pregnancy; prolactin; SLEDAI; systemic lupus erythematosus; treatment; GLYCOL PRECIPITATION TEST; DISEASE-ACTIVITY; MOLECULAR HETEROGENEITY; CLINICAL ACTIVITY; B-CELLS; SERUM; HYPERPROLACTINEMIA; AUTOANTIBODIES; FREQUENCY; PRL;
D O I
10.2174/1871530315666151020101518
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The correlation of prolactin (PRL) levels with SLE activity is a controversial issue, which could be explained by the presence of macroprolactin (MPRL), a high molecular weight form of PRL with a lower in vivo biological activity. Objectives: We aimed to evaluate the prevalence of hyperprolactinemia, PRL and MPRL levels in SLE patients, and to correlate these levels with disease activity as measured by the SLE Disease Activity Index (SLEDAI). Material and Methods: We conducted a case-control, cross-sectional study with 73 SLE patients (L group), sixty-two of which were evaluated before and after treatment, and correlated the results with serum PRL and MPRL levels. These results were compared to those of 29 healthy women with ovulatory cycles (C group) and 34 women in the third trimester of pregnancy (G group). Results: Mean PRL levels were: 8,8 ng/ml on C group; 12,0 ng/ml on L group (p = 0.02) and 158,5 ng/ml on G group. Hyperprolactinemia was present in 19.4% of SLE patients, but was not found on C group. The MPRL form was predominant among 20.5% of SLE patients, in none of the C group and in only 5.8% of pregnant women. There was a strong correlation between the PRL levels and SLE activity, regardless of the hormone's molecular form. SLE treatment was able to reduce levels of all forms of PRL. The predominance of MPRL, however, did not change after treatment. Conclusions: Despite its lower biological activity, MPRL levels correlated with LES activity as much as free prolactin.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 55 条
[1]   SUPPRESSION OF MACROPHAGE ACTIVATION AND LYMPHOCYTE-T FUNCTION IN HYPOPROLACTINEMIC MICE [J].
BERNTON, EW ;
MELTZER, MS ;
HOLADAY, JW .
SCIENCE, 1988, 239 (4838) :401-404
[2]   FREQUENCY OF HYPERPROLACTINEMIA DUE TO LARGE MOLECULAR-WEIGHT PROLACTIN (150-170-KD PRL) [J].
BJORO, T ;
MORKRID, L ;
WERGELAND, R ;
TURTER, A ;
KVISTBORG, A ;
SAND, T ;
TORJESEN, P .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 (02) :139-147
[3]   Analysis of anti-prolactin autoantibodies in systemic lupus erythematosus [J].
Blanco-Favela, F ;
Chavez-Rueda, K ;
Leaños-Miranda, A .
LUPUS, 2001, 10 (10) :757-761
[4]   Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice [J].
Bole-Feysot, C ;
Goffin, V ;
Edery, M ;
Binart, N ;
Kelly, PA .
ENDOCRINE REVIEWS, 1998, 19 (03) :225-268
[5]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[6]  
Buskila D, 1996, J RHEUMATOL, V23, P629
[7]  
Chavez-Rueda K, 2005, CLIN EXP RHEUMATOL, V23, P769
[8]   Prolactin and neuroimmunomodulation:: In vitro and in vivo observations [J].
Chikanza, IC .
NEUROENDOCRINE IMMUNE BASIS OF THE RHEUMATIC DISEASES, 1999, 876 :119-130
[9]   Prolactin: A versatile regulator of inflammation and autoimmune pathology [J].
Costanza, Massimo ;
Binart, Nadine ;
Steinman, Lawrence ;
Pedotti, Rosetta .
AUTOIMMUNITY REVIEWS, 2015, 14 (03) :223-230
[10]  
Cruz J, 2001, ARTHRITIS RHEUM, V44, P1331, DOI 10.1002/1529-0131(200106)44:6<1331::AID-ART225>3.0.CO